As of 2026-03-21, the EV/EBITDA ratio of Ionis Pharmaceuticals Inc (IONS) is -30.07. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. IONS's latest enterprise value is 13,685.32 mil USD. IONS's TTM EBITDA according to its financial statements is -455.05 mil USD. Dividing these 2 quantities gives us the above IONS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.6x - 23.9x | 14.0x |
| Forward P/E multiples | 12.5x - 23.1x | 14.9x |
| Fair Price | (46.23) - (75.54) | (51.66) |
| Upside | -165.1% - -206.4% | -172.8% |
| Date | EV/EBITDA |
| 2026-03-17 | -30.56 |
| 2026-03-16 | -30.56 |
| 2026-03-13 | -30.15 |
| 2026-03-12 | -30.56 |
| 2026-03-11 | -31.45 |
| 2026-03-10 | -31.77 |
| 2026-03-09 | -31.66 |
| 2026-03-06 | -31.18 |
| 2026-03-05 | -31.59 |
| 2026-03-04 | -33.15 |
| 2026-03-03 | -32.86 |
| 2026-03-02 | -34.06 |
| 2026-02-27 | -33.76 |
| 2026-02-26 | -33.56 |
| 2026-02-25 | -33.68 |
| 2026-02-24 | -35.32 |
| 2026-02-23 | -35.01 |
| 2026-02-20 | -34.49 |
| 2026-02-19 | -34.49 |
| 2026-02-18 | -34.15 |
| 2026-02-17 | -33.84 |
| 2026-02-13 | -33.56 |
| 2026-02-12 | -33.99 |
| 2026-02-11 | -34.92 |
| 2026-02-10 | -34.90 |
| 2026-02-09 | -35.08 |
| 2026-02-06 | -35.70 |
| 2026-02-05 | -34.61 |
| 2026-02-04 | -35.16 |
| 2026-02-03 | -35.01 |
| 2026-02-02 | -34.46 |
| 2026-01-30 | -34.31 |
| 2026-01-29 | -34.75 |
| 2026-01-28 | -34.04 |
| 2026-01-27 | -34.12 |
| 2026-01-26 | -33.71 |
| 2026-01-23 | -33.45 |
| 2026-01-22 | -33.99 |
| 2026-01-21 | -33.14 |
| 2026-01-20 | -32.45 |
| 2026-01-16 | -32.01 |
| 2026-01-15 | -32.33 |
| 2026-01-14 | -32.93 |
| 2026-01-13 | -33.16 |
| 2026-01-12 | -33.95 |
| 2026-01-09 | -33.45 |
| 2026-01-08 | -33.90 |
| 2026-01-07 | -34.50 |
| 2026-01-06 | -33.89 |
| 2026-01-05 | -32.81 |